Search
MoonLake Immunotherapeutics
MLTXAdd to Watchlist
12.500USD
-0.370-2.87%
Close 11-13 16:00（ET）
1.06BMarket Cap
LossP/E TTM
MLTX Analyst Recommendation Trends
In the current month, MLTX has received 7 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. MLTX average Analyst price target in the last month is 31.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
5
6
6
5
7
7
7
7
7
7
7
6
2
2
2
2
2
2
2
3
1
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
16
16
16
16
16
17
17
17
Financial Forecasting
Based on analysts' estimates, MLTX EPS is projected to reach -0.833 in FY2026Q4, following reported EPS of -0.932 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.89
-0.92
-0.78
-0.83
-0.85
Actual
-0.98
-0.84
-0.93
--
--
Surprise
-9.66%
+8.98%
-18.92%
--
--
FAQs
How have MoonLake ImmunotherapeuticsMLTX's recent earnings per share performed?
The market expectation was USD -0.93, while MoonLake ImmunotherapeuticsMLTX's earnings per share (EPS) for the previous quarter was USD -0.84. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for MoonLake Immunotherapeutics?
Based on the ratings of MoonLake Immunotherapeutics's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.